167 related articles for article (PubMed ID: 21192264)
21. Modelling the lifetime economic consequences of glaucoma in France.
Philippe Nordmann J; Lafuma A; Berdeaux G
J Med Econ; 2009 Mar; 12(1):9-16. PubMed ID: 19450060
[TBL] [Abstract][Full Text] [Related]
22. Clinical and economic impact of new trends in glaucoma treatment.
Marchetti A; Magar R; An P; Nichol M
MedGenMed; 2001 Jul; 3(4):6. PubMed ID: 11549985
[TBL] [Abstract][Full Text] [Related]
23. A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy.
Christensen TL; Poulsen PB; Holmstrom S; Walt JG; Vetrugno M
Curr Med Res Opin; 2005 Nov; 21(11):1837-44. PubMed ID: 16307705
[TBL] [Abstract][Full Text] [Related]
24. Costs of a community-based glaucoma detection programme: analysis of the Philadelphia Glaucoma Detection and Treatment Project.
Pizzi LT; Waisbourd M; Hark L; Sembhi H; Lee P; Crews JE; Saaddine JB; Steele D; Katz LJ
Br J Ophthalmol; 2018 Feb; 102(2):225-232. PubMed ID: 28655730
[TBL] [Abstract][Full Text] [Related]
25. Glaucoma Control Strategies in Sub-Saharan Africa: A Review of the Clinical and Health Economic Evidence.
Smith AF; Negretti G; Mascaro A; Bokre D; Baker H; Dhalla K; Murdoch IE
Ophthalmic Epidemiol; 2018; 25(5-6):419-435. PubMed ID: 30059637
[TBL] [Abstract][Full Text] [Related]
26. Comments on: Current concepts in the pathogenesis and management of exfoliation syndrome and exfoliative glaucoma.
Brooks AM
Compr Ophthalmol Update; 2006; 7(3):143-4. PubMed ID: 16882402
[No Abstract] [Full Text] [Related]
27. How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications.
De Natale R; Draghi E; Dorigo MT
Acta Ophthalmol Scand; 2004 Aug; 82(4):393-6. PubMed ID: 15291930
[TBL] [Abstract][Full Text] [Related]
28. Cost analysis of glaucoma medications.
Rylander NR; Vold SD
Am J Ophthalmol; 2008 Jan; 145(1):106-13. PubMed ID: 18154755
[TBL] [Abstract][Full Text] [Related]
29. Cost analysis of glaucoma medications.
Fiscella RG; Jensen MK
Am J Ophthalmol; 2008 Jun; 145(6):1108-9; author reply 1109. PubMed ID: 18503789
[No Abstract] [Full Text] [Related]
30. Glaucoma screening: current perspectives and future directions.
Momont AC; Mills RP
Semin Ophthalmol; 2013 May; 28(3):185-90. PubMed ID: 23697622
[TBL] [Abstract][Full Text] [Related]
31. Health economics, economic evaluation, and glaucoma.
Kobelt G
J Glaucoma; 2002 Dec; 11(6):531-9. PubMed ID: 12483101
[TBL] [Abstract][Full Text] [Related]
32. [Economic aspects. Cost-effectiveness, cost-benefit analysis].
Durieux P
Rev Mal Respir; 1998 Sep; 15 Suppl 2():S37-41. PubMed ID: 9809342
[No Abstract] [Full Text] [Related]
33. Treatment of glaucoma in clinical practice: four-year results from a patient registry in France.
Kobelt G; Texier-Richard B; Buchholz P; Bron A; Renard JP; Rouland JF; Nordmann JP
J Glaucoma; 2010 Mar; 19(3):199-206. PubMed ID: 19661825
[TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients--a European perspective.
Tuil E; Hommer AB; Poulsen PB; Christensen TL; Buchholz P; Walt J; Holmstrom S
Int J Clin Pract; 2005 Sep; 59(9):1011-6. PubMed ID: 16115174
[TBL] [Abstract][Full Text] [Related]
35. Evaluation and management of glaucoma after keratoprosthesis.
Banitt M
Curr Opin Ophthalmol; 2011 Mar; 22(2):133-6. PubMed ID: 21191292
[TBL] [Abstract][Full Text] [Related]
36. Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study.
Gieser DK; Tracy Williams R; O'Connell W; Pasquale LR; Rosenthal BP; Walt JG; Katz LM; Siegartel LR; Wang L; Rosenblatt LC; Stern LS; Doyle JJ
J Glaucoma; 2006 Oct; 15(5):419-25. PubMed ID: 16988605
[TBL] [Abstract][Full Text] [Related]
37. Current concepts in the pathogenesis and management of exfoliation syndrome and exfoliative glaucoma.
Konstas AG; Tsironi S; Ritch R
Compr Ophthalmol Update; 2006; 7(3):131-41. PubMed ID: 16882401
[TBL] [Abstract][Full Text] [Related]
38. Money matters: what to look for in an economic analysis.
Dijksman LM; Poolman RW; Bhandari M; Goeree R; Tarride JE;
Acta Orthop; 2008 Feb; 79(1):1-11. PubMed ID: 18283565
[No Abstract] [Full Text] [Related]
39. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States.
Kobelt-Nguyen G; Gerdtham UG; Alm A
J Glaucoma; 1998 Apr; 7(2):95-104. PubMed ID: 9559495
[TBL] [Abstract][Full Text] [Related]
40. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
